Use of CA-125 in clinical trial evaluation of new therapeutic drugs for ovarian cancer.
Rustin
Gordon J S
GJ
Department of Medical Oncology, Mount Vernon Cancer Centre, Northwood, Middlesex, United Kingdom. rustin@mtvern.co.uk
Bast
Robert C
RC
Kelloff
Gary J
GJ
Barrett
J Carl
JC
Carter
Stephen K
SK
Nisen
Perry D
PD
Sigman
Caroline C
CC
Parkinson
David R
DR
Ruddon
Raymond W
RW
D014408:Biomarkers, Tumor; D018394:CA-125 Antigen / Q000096:biosynthesis*; D002986:Clinical Trials as Topic; D018572:Disease-Free Survival; D015195:Drug Design; D004341:Drug Evaluation; D005260:Female; D006801:Humans; D010051:Ovarian Neoplasms / Q000188:drug therapy* / Q000378:metabolism* / Q000401:mortality; D011379:Prognosis; D012107:Research Design; D016896:Treatment Outcome
D014408:Biomarkers, Tumor; D018394:CA-125 Antigen